Tagged with GE

Celgene Taiwan Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene is very new entrant in the multinational context as a latecomer to the market. As a biopharmaceutical company it is…

France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…

Medigen Biotechnology Corp. Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen? Medigen was registered at the MOEA in 1999, but the company was actually established in 2000. In the beginning, the…

Genovate Genovate was founded in 1995. It is a very interesting story: a mix of biotech, the history with American company Genelabs, government investments and also private investment through Chinachem. Can you tell our readers how this company came into existence, what attracted the stakeholders to invest in the company? After…

Abiogen You created Abiogen in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition, keeping building on the legacy of your great-grandfather Commendatore Alfredo Gentili, combining it with your personal innovative vision to create a “new reality”. To have a better understanding of…

Celgene France In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head of Celgene France’s operations, what were the main milestones of the company since its establishment in the French market in…

Stallergenes Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the group. On average we have grown 15% meaning in the past decade our sales have quadrupled our turnover. These results…

Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…

Boehringer Ingelheim France There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these new facilities here at Paris Biopark. What does this express about the moves Boehringer Ingelheim is taking in France and…

Biogen Idec Germany Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The growth potential of the biotech industry is incomparable to any other sector in the pharmaceutical industry, and the entire industry…

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…